Scalability

The only cell-engineering technology able to scale from early-stage R&D to global patient treatment.

 

Flow Electroporation™ Technology scales in two ways – from small- to large-scale on a single instrument and from one MaxCyte Scalable Transfection System to another.

  • Half a million (0.5 x 106) cells within seconds up to 200 billion (2 x 1011) cells in <30 minutes
  • Transfect from <1 mL to up to 200L of cell culture
  • No re-optimization required
  • High transfection efficiency and high cell viability maintained at all scales

 

 

Simply Scalability with No Reoptimization Required

 

Other transfection technologies require multiple small-scale transfections, reoptimization of transfection protocols and/or bulk usage of costly reagents for larger scale transfection. MaxCyte electroporation seamlessly scales requiring no further assay optimization with transfection quality and cell performance in downstream applications unaffected by scale up.

Small-scale electroporation is conducted using an OC-100, OC-400 or CL-1.1 processing assembly (PA). The PA is loaded on a MaxCyte Scalable Transfection System and the entire aliquot of cells is electroporated within seconds.  A CL-2 (MaxCyte STX) or VLXD (MaxCyte VLX) PA is used for large-scale electroporation in which 3 mL fractions flow in succession through the electroporation chamber and continue into the cell collection bag. Up to 2×1011 cells can be transfected in < 30 minutes.

 

Consistent Delivery throughout Large-Scale Electroporation

 

 

4×107 K562 cells were transfected with pGFP DNA using small-scale electroporation. Additionally, 6×109 cells were transfected using large-scale electroporation. 28 fractions throughout the electroporation run were collected. All cells were assessed for cell viability and transfection efficiency 24 hours post transfection.

Scale up on the MaxCyte STX for Multi-gram Protein Production 

 

 

CHO-S cells were transfected with an IgG expression plasmid via small- or large-scale electroporation using the MaxCyte STX. Antibody titers >1.2 grams/L were detected within two weeks of transient transfection for both transfections. A total of 3.4 grams of antibody was produced from a 2.8 L culture following a single transfection.

 

Scale-Up of Lentiviral Vector Production Using the MaxCyte Delivery Platform

 

Suspension-adapted HEK 293FT cells were mixed with four plasmids encoding lentiviral vector components (0.4µg of DNA/1E6 cells), and cells transferred to sterile OC-400, CL-2 and VLXD processing assemblies. Cells in the OC-400 and CL-2 were transfected by small- and large-scale electroporation, respectively, using the STX instrument; cells in the VLXD were transfected on the MaxCyte VLX. Lentiviral titers were measured after 24-48 hours in culture. Normalized titer data show seamless scalability of the MaxCyte delivery platform.

Easily Scale-Up for Screening, Eliminating the Need for Stable Cell Lines.

 

Cells were transfected with eGFP-2XFYVE (tandem PI3P binding domains fused to eGFP) using small-scale (SCEP) or large-scale (LSEP) electroporation. Transfected cells or cells stably expressing eGPF-2XFYVE were incubated for 30 minutes with wortmannin, a PI3 kinase inhibitor.

Scale-Up of a Dual Plasmid Nuclear Receptor Assay

 

 

 

U2OS cells co-transfected with equimolar ratio of nuclear hormone receptor and reporter plasmids. 4×107 cells were transfected by small scale electroporation in an OC-400 processing assembly; 1×109 cells were transfected by large scale electroporation in a CL-2 processing assembly. Cells were assayed 24 hours post electroporation.

Resource Center

Which MaxCyte System Has the Scale You Need?

Read More
Request Demo